Psoriatic arthritis impacts skin and joints. It causes pain, swelling, and stiffness. This condition often follows psoriasis.

Dr Philip Mease explores how modern imaging tools are reshaping the understanding of joint damage and progression in ...

A new treatment for a debilitating inflammatory condition which affects joints and skin has shown promising early results in ...

Upadacitinib and secukinumab for PsA offers comparable improvements in skin and joint symptoms, but adalimumab offers superior pain relief.

Adults with psoriatic arthritis saw early improvements in their symptoms and key health-related quality-of-life measures with ...

Called sonelokimab, the product inhibits both the A and F isoforms of interleukin-17 (IL-17). In this mid-stage trial, well ...

Soung also spoke at the 2025 Skin of Color Update, addressing multidisciplinary approaches to treating comorbidities in ...

Treatment with guselkumab led to improvements in disease activity over 1 year among patients with PsA and showed a high retention rate.

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of plaque ...

Patients with PsA have a higher prevalence of MetS compared with members of the general population and individuals with other inflammatory arthropathies.

The FDA has expanded the approval of Tremfya to include pediatric patients 6 years and older weighing at least 40kg for the treatment of moderate to severe plaque PsO and active PsA.